Demand for Experimental Ebola Drug Soars

The World Health Organization has approved the use of ZMapp, but supplies are extremely limited.
1:32 | 08/12/14

Coming up in the next {{countdown}} {{countdownlbl}}

Coming up next:



Skip to this video now

Now Playing:


Related Extras
Related Videos
Video Transcript
Transcript for Demand for Experimental Ebola Drug Soars
Major developments in the ebola outbreak, more than 1,000 lives lost and the debate over the untested but promising experimental treatment. Those two sick Americans got it, but what about the thousands of patience on the ground in Africa? Here's ABC's Mara schiavocampo. Reporter: Tonight, the world health organization has approved the use of Z- Mapp to combat ebola, calling it "The largest, most severe and most complex outbreak of ebola virus disease in history." That drug has shown so much promise, it's been given to two American aid workers being treated for ebola in Atlanta. While they both improved, many others are in desperate need and demand for the drug is soaring. But z-mapp has not been supplied to the africans who make up the majority of the victims. The ethical question is how we decide who should get it. We want to make sure we have clear criteria to make sure it's done fairly. Reporter: The drug made from tobacco plants in the U.S. Can take weeks to produce. Tonight the manufacturer says the available supply has been exhausted. That drug is being made in Kentucky, and medical experts say it will likely be the end of the year before they have enough new supply to begin trials on humans. Important studies. Mara, thank you. There's still much more ahead on "World news" this Tuesday night.

This transcript has been automatically generated and may not be 100% accurate.

{"duration":"1:32","description":"The World Health Organization has approved the use of ZMapp, but supplies are extremely limited.","mediaType":"default","section":"ABCNews/WNT","id":"24954413","title":"Demand for Experimental Ebola Drug Soars","url":"/WNT/video/ebola-outbreak-demand-experimental-drug-soars-24954413"}